- Product Details
Keywords
- LOXO-292
- Selpercatinib
- LOXO292
Quick Details
- ProName: Pharmaceutical raw material Selpercati...
- CasNo: 2152628-33-4
- Molecular Formula: C29H31N7O3
- Appearance: white powder
- Application: used by athletes to assist in training...
- DeliveryTime: immediately
- PackAge: aluminum foil bag
- Port: HK, Shanghai, Shenzhen
- ProductionCapacity: 100 Kilogram/Month
- Purity: 99%
- Storage: cool and dry place
- Transportation: EMS,DHL,HK post,EUB,ETK,NL post,German...
- LimitNum: 1 Gram
Superiority
Details
Product name | LOXO-292 Selpercatinib |
Selpercatinib Chemical properties |
Chemical name: 6-(2-hydroxy-2-methylpropoxy)-4-(6-{6-[(6-methoxypyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl}pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
CAS #: 2152628-33-4 | |
chemical structure: | |
Appearance: white powder
|
|
Other names: LOXO-292, Selpercatinib |
|
what is Loratadine |
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including cabozantinib, ponatinib, sorafenib, sunitinib, and vandetanib, have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers. |
Packing and shipping